Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Jianhua ShiGuimin ChenHaitao WangXiuxiu WangBao-Hui HanKai LiQiming WangLi ZhangZhehai WangYing ChengJianxing HeYuan-Kai ShiWeiqiang ChenYi LuoLin WuXiuwen WangKejun NanFaguang JinJian DongBaolan LiZhian LiuPublished in: Thoracic cancer (2021)
The occurrence of hypertension might be a clinical indicator predicting the efficacy of third-line anlotinib treatment in patients with SCC.